 FRAMINGHAM, MA ACCESSWIRE March 3, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCARTTM, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. 